Objective To investigate a potential relationship between Solute carrier family 30 (zinc transporter) member 8 (SLC30A8) rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients.Methods A total of 209 diabetic patients without any antihyperglycemic history were recruited and treated with repaglinide or rosiglitazone randomly for 48 weeks (104 and 105 patients,respectively).Anthropometric measurements and clinical laboratory tests were carried out before and after the treatment.An non-synonymous variant rs13266634 was genotyped by matrix-assisted laser desorption ionization-time of flight mass spectroscopy.Results Ninety-one patients in repaglinide group and ninety-three patients in rosiglitazone group completed the study.Δ value of homeostasis model assessment of beta cell function (HOMA-B)and Δ value of fasting proinsulin levels were statistically significant between three genotype groups (P=0.0149 and 0.0246,respectively) after rosiglitazone treatment.However,no genotype association was observed in the repaglinide or rosiglitazone group with other parameters.Conclusion The SLC30A8 variant was associated with the efficacy of insulin sensitizer monotherapy on insulin secretion in patients with newly diagnosed type 2 diabetes mellitus in Shanghai,China.
目的探讨蛋白酪氨酸磷酸酶抗体(IA-2A)对成人隐匿性自身免疫性糖尿病(LADA)的诊断价值。方法采用放射配体法检测2 027例初诊2型糖尿病(T2DM)患者的IA-2A和谷氨酸脱羧酶抗体(GAD-Ab),分析IA-2A在初诊T2DM患者中的分布及其与临床特征的关系。结果初诊T2DM患者中IA-2A阳性检出率低于GAD-Ab阳性检出率(2.2% vs 10.6%,P<0.01)。联合GAD-Ab和IA2A检测,可使LADA阳性检出率达11.5%。IA-2A在低体重、低C肽水平患者中阳性检出率高;随着起病年龄增大,IA-2A阳性检出率下降(P<0.05)。与T2DM组比较,单独IA-2A阳性患者使用胰岛素治疗的比例高(P<0.05)。高滴度IA-2A阳性LADA患者具有起病年龄小(P<0.01)、体重轻、高血压比例低、空腹C肽低、合并GAD-Ab阳性和使用胰岛素比例高(P<0.05)等特点。结论 IA-2A检测对LADA具有辅助诊断价值,与GAD-Ab联合检测可提高LADA诊断的敏感性。
